Systematic Review and Meta-Analysis of Surgical Treatment for Isolated Local Recurrence of Pancreatic Cancer

To perform a systematic review and meta-analysis on the outcome of surgical treatment for isolated local recurrence of pancreatic cancer. A systematic review and meta-analysis based on Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was conducted in PubMed, Sco...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-03, Vol.13 (6), p.1277
Main Authors: Serafini, Simone, Sperti, Cosimo, Friziero, Alberto, Brazzale, Alessandra Rosalba, Buratin, Alessia, Ponzoni, Alberto, Moletta, Lucia
Format: Article
Language:English
Subjects:
Cancer therapies
Chemotherapy
Lymphatic system
Medical prognosis
Meta-analysis
Mortality
Pancreatic cancer
Patients
Surgery
Survival
Systematic Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To perform a systematic review and meta-analysis on the outcome of surgical treatment for isolated local recurrence of pancreatic cancer. A systematic review and meta-analysis based on Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was conducted in PubMed, Scopus, and Web of Science. Six studies concerning 431 patients with recurrent pancreatic cancer met the inclusion criteria and were included in the analysis: 176 underwent redo surgery, and 255 received non-surgical treatments. Overall survival and post-recurrence survival were significantly longer in the re-resected group (ratio of means (ROM) 1.99; 95% confidence interval (CI), 1.54-2.56, = 75.89%, = 0.006, and ROM = 2.05; 95% CI, 1.48-2.83, = 76.39%, = 0.002, respectively) with a median overall survival benefit of 28.7 months (mean difference (MD) 28.7; 95% CI, 10.3-47.0, = 89.27%, < 0.001) and median survival benefit of 15.2 months after re-resection (MD 15.2; 95% CI, 8.6-21.8, = 58.22%, = 0.048). Resection of isolated pancreatic cancer recurrences is safe and feasible and may offer a survival benefit. Selection of patients and assessment of time and site of recurrence are mandatory.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13061277